![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Odes Selwyn
Publisher: Informa Healthcare
ISSN: 1472-8214
Source: Expert Opinion on Emerging Drugs, Vol.18, Iss.1, 2013-03, pp. : 1-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Hormone-Refractory Prostate Cancer: Where are We Going?
Drugs, Vol. 67, Iss. 8, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
What's new in disease management?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 252, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Rosiglitazone: novel therapy for ulcerative colitis?
Inpharma, Vol. 1, Iss. 1322, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Long-term antibacterial therapy: a role in ulcerative colitis?
Inpharma, Vol. 1, Iss. 1304, 2001-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Ursodeoxycholic acid provides chemoprotection in ulcerative colitis?
Inpharma, Vol. 1, Iss. 1390, 2003-01 ,pp. :